Author Index

Ada, G.L. What to expect of a good vaccine and how to achieve it, 77
Adamowicz, P. *see* Coursaget, P., 357
Addo, P.B., *see* Okoh, A.E.J., 19
Ahuja, S. *see* Gupta, R.K., 491
Aizawa, C. *see* Tamura, S., 409
Ajioka, R. *see* Seifert, H.S., 107
Alexandrova, G.I. *see* Slepushkin, A.N., 25
Anderson, P. and Insel, R.A. Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of *Haemophilus influenzae* type b, 188
Arita, M. *see* Nomoto, A., 134
Arrhenius, T. *see* Satterthwait, A.C., 99
Artamonov, A.F. *see* Berezin, V.E., 450
Arya, S.C. Continuing global poliomyelitis morbidity and lacunae of trivalent poliovirus vaccines, 213
Arya, S.C. Enhancement of field stability and utility of future biologicals through prior accelerated degradation testing, 386
Arya, S.C. Stability of oral polio vaccine at different temperatures, 298
Arya, S.C. Testing for AIDS on samples of dried blood on filter papers, 210
Asada, H. *see* Yamanishi, K., 278
Ashworth, L.A.E. *see* Rutter, D.A., 29
Attridge, S., Hackett, J., Morona, R. and Whyte, P. Towards a live oral vaccine against enterotoxigenic *Escherichia coli* of swine, 387
Azuma, I. *see* Ishida, H., 440
Azuma, I. *see* Saiki, I., 238
Azuma, I., Saiki, I., Iida, J., Fukuda, T. and Kobayashi, S. Immunological activities of multiprenylacetyl derivatives of muramyl dipeptides, 339

Baklaic, Z. *see* Vodopija, I., 283, 489
Bakouche, O. *see* Mougin, B., 445
Barres, J.L. *see* Coursaget, P., 357
Barrett, A.D.T. *see* Gibson, C.A., 7
Barth, R., Diderrich, G. and Weinmann, E. NIH test, a problematic method for testing potency of inactivated rabies vaccine, 369
Beachey, E.H., Bronze, M., Dale, J.B., Kraus, W., Poirier, T. and Sargent, S. Protective and autoimmune epitopes of streptococcal M proteins, 192
Beale, A.J. Vaccine development reconsidered, 138
Beeler, J.A. *see* Olmsted, R.A., 519
Benda, R. *see* Kutinova, L., 223
Berezin, V.E., Zaides, V.M., Isaeva, E.S. Artamonov, A.F. and Zhdanov, V.M. Controlled organization of multimolecular complexes of enveloped virus glycoproteins: study of immunogenicity, 450
Berg, U. *see* Kreuter, J., 253
Berger, R. *see* Just, M., 399, 401
Bergmann, I.E., Tiraboschi, B., Mazzuca, G., Fernandez, E., Michiloff, C.A., Scodeller, E.A. and La Torre, J.L. Serological and biochemical analysis of foot-and-mouth disease virus (serotype C3) isolated in Argentina between 1981 and 1986, 245
Berzins, K. *see* Perlmann, P., 183
Berzofsky, J.A. Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity, 89
Beuvery, E.C. *see* Speijers, G.J.A., 419
Bona, C.A. *see* Ertl, H.C.J., 80
Boriskin, Y.S., Kaptsova, T.I., Lotte, V.D., Skvortsova, O.I. and Orvell, C. Laboratory markers for overattenuation of mumps vaccine virus, 483
Bos, C.A. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model, 309
Boulay, G. *see* Trudel, M., 525
Bourdil, C. *see* Coursaget, P., 357
Bourhy, H. *see* Lafon, M., 362
Breukers, A.A.F.M. *see* Heijtink, R.A., 59
Bronze, M. *see* Beachey, E.H., 192
Brown, F. Use of peptides for immunization against foot-and-mouth disease, 180
Bruck, C. *see* Goudsmit, J., 229
Buisson, Y. *see* Coursaget, P., 357
Buller, R.M.L. *see* Olmsted, R.A., 519

Cahill, A.D. *see* Greenwood, P.E., 389
Celada, F. and Sercarz, E.E. Preferential pairing of T–B specificities in the same antigen: the concept of directional help, 94
Chanock, R.M. *see* Olmsted, R.A., 519
Chanock, R.M., Murphy, B.R., Collins, P.L., Coelingh, K.V.W., Olmsted, R.A., Snyder, M.H., Spriggs, M.K., Prince, G.A., Moss, B., Flores, J., Goziglia, M. and Kapikian, A.Z. Live viral vaccines for respiratory and enteric tract diseases, 129
Charbonnier, C. *see* Kleitmann, W., 39
Cheshik, S.G. *see* Slepushkin, A.N., 25
Chiron, J.-P. *see* Coursaget, P., 357
Cioni, C. *see* Ubertini, T.R., 481
Clark, S.J. *see* Greenwood, P.E., 389
Clements, J.D., Hartzog, N.M. and Lyon, F.L. Adjuvant activity of *Escherichia coli* heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens, 269
Coelingh, K.V.W. *see* Chanock, R.M., 129
Cohen, J.H.M. *see* Fessard, C., 469
Collins, P.L. *see* Olmsted, R.A., 519
Collins, P.L. *see* Chanock, R.M., 129
Coursaget, P., Adamowicz, P., Bourdil, C., Yvonnet, B., Buisson, Y., Barres, J.L., Saliou, P., Chiron, J.-P. and Mar, I.D. Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization, 357
Cox, J. *see* Kleitmann, W., 39
Cox, N.J. *see* De, B.K., 257
Curtiss, R., Goldschmit, R.M., Fletchall, N.B. and Kelly, S.M. Avirulent *Salmonella typhimurium* Δcya Δcrp oral vaccine strains expressing a streptococcal colonization and virulence antigen, 155
Czuprynski, C.J. *see* Noel, E.J., 433

Dale, J.B. *see* Beachey, E.H., 192
Dalgleish, A.G. and Kennedy, R.C. Anti-idiotype antibodies as immunogens: idiotype-based vaccines, 215
Danse, L.H.J.C. *see* Speijers, G.J.A., 419
Day, A. *see* Rutter, D.A., 29
Dbaly, V. *see* Kutinova, L., 223
De, B.K., Shaw, M.W., Rota, P.A., Harmon, M.W., Esposito, J.J., Rott, R., Cox, N.J. and Kendal, A.P. Protection against virulent H5 avian influenza infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus, 257
den Hartigh, G. *see* Heijtink, R.A., 59
Derks, H.J.G.M. *see* Speijers, G.J.A., 419
Desmettre, P. *see* Taylor, J., 497
Deveikis, A., Ward, J. and Kim, K.S. Functional activities of human antibody induced by the capsular polysaccharide or polysaccharide-conjugate vaccines against *Haemophilus influenzae* type b, 14
Dewar, J.B. *see* Martin, M.E.D., 33
Diderrich, G. *see* Barth, R., 369
Domorazkova, E. *see* Kutinova, L., 223
Doutlik, S. *see* Kutinova, L., 223
Dubois, D.R. *see* Eckels, K.H., 513

Eckels, K.H., Yong-Xin, Y., Dubois, D.R., Marchette, N.J., Trent, D.W. and Johnson, A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaption to primary canine kidney cell cultures and preparation of a vaccine for human use, 513
EEC Research Working Party on AIDS. Towards anti-HIV vaccines, 211
Eichmann, K. and Emmrich, F. Selective induction of T-cell subsets by antibodies to the T-cell antigen receptor and the subset-specific differentiation antigens CD8 and CD4, 85

Author Index

Ada, G.L. What to expect of a good vaccine and how to achieve it, 77
Adamowicz, P. *see* Coursaget, P., 357
Addo, P.B., *see* Okoh, A.E.J., 19
Ahuja, S. *see* Gupta, R.K., 491
Aizawa, C. *see* Tamura, S., 409
Ajioka, R. *see* Seifert, H.S., 107
Alexandrova, G.I. *see* Slepushkin, A.N., 25
Anderson, P. and Insel, R.A. Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of *Haemophilus influenzae* type b, 188
Arita, M. *see* Nomoto, A., 134
Arrhenius, T. *see* Satterthwait, A.C., 99
Artamonov, A.F. *see* Berezin, V.E., 450
Arya, S.C. Continuing global poliomyelitis morbidity and lacunae of trivalent poliovirus vaccines, 213
Arya, S.C. Enhancement of field stability and utility of future biologicals through prior accelerated degradation testing, 386
Arya, S.C. Stability of oral polio vaccine at different temperatures, 298
Arya, S.C. Testing for AIDS on samples of dried blood on filter papers, 210
Asada, H. *see* Yamanishi, K., 278
Ashworth, L.A.E. *see* Rutter, D.A., 29
Attridge, S., Hackett, J., Morona, R. and Whyte, P. Towards a live oral vaccine against enterotoxigenic *Escherichia coli* of swine, 387
Azuma, I. *see* Ishida, H., 440
Azuma, I. *see* Saiki, I., 238
Azuma, I., Saiki, I., Iida, J., Fukuda, T. and Kobayashi, S. Immunological activities of multiprenylacetyl derivatives of muramyl dipeptides, 339

Baklaic, Z. *see* Vodopija, I., 283, 489
Bakouche, O. *see* Mougin, B., 445
Barres, J.L. *see* Coursaget, P., 357
Barrett, A.D.T. *see* Gibson, C.A., 7
Barth, R., Diderrich, G. and Weinmann, E. NIH test, a problematic method for testing potency of inactivated rabies vaccine, 369
Beachey, E.H., Bronze, M., Dale, J.B., Kraus, W., Poirier, T. and Sargent, S. Protective and autoimmune epitopes of streptococcal M proteins, 192
Beale, A.J. Vaccine development reconsidered, 138
Beeler, J.A. *see* Olmsted, R.A., 519
Benda, R. *see* Kutinova, L., 223
Berezin, V.E., Zaides, V.M., Isaeva, E.S. Artamonov, A.F. and Zhdanov, V.M. Controlled organization of multimolecular complexes of enveloped virus glycoproteins: study of immunogenicity, 450
Berg, U. *see* Kreuter, J., 253
Berger, R. *see* Just, M., 399, 401
Bergmann, I.E., Tiraboschi, B., Mazzuca, G., Fernandez, E., Michiloff, C.A., Scodeller, E.A. and La Torre, J.L. Serological and biochemical analysis of foot-and-mouth disease virus (serotype C3) isolated in Argentina between 1981 and 1986, 245
Berzins, K. *see* Perlmann, P., 183
Berzofsky, J.A. Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity, 89
Beuvery, E.C. *see* Speijers, G.J.A., 419
Bona, C.A. *see* Ertl, H.C.J., 80
Boriskin, Y.S., Kaptsova, T.I., Lotte, V.D., Skvortsova, O.I. and Orvell, C. Laboratory markers for overattenuation of mumps vaccine virus, 483
Bos, C.A. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model, 309
Boulay, G. *see* Trudel, M., 525
Bourdil, C. *see* Coursaget, P., 357
Bourhy, H. *see* Lafon, M., 362
Breukers, A.A.F.M. *see* Heijtink, R.A., 59
Bronze, M. *see* Beachey, E.H., 192
Brown, F. Use of peptides for immunization against foot-and-mouth disease, 180
Bruck, C. *see* Goudsmit, J., 229
Buisson, Y. *see* Coursaget, P., 357
Buller, R.M.L. *see* Olmsted, R.A., 519

Cahill, A.D. *see* Greenwood, P.E., 389
Celada, F. and Sercarz, E.E. Preferential pairing of T–B specificities in the same antigen: the concept of directional help, 94
Chanock, R.M. *see* Olmsted, R.A., 519
Chanock, R.M., Murphy, B.R., Collins, P.L., Coelingh, K.V.W., Olmsted, R.A., Snyder, M.H., Spriggs, M.K., Prince, G.A., Moss, B., Flores, J., Goziglia, M. and Kapikian, A.Z. Live viral vaccines for respiratory and enteric tract diseases, 129
Charbonnier, C. *see* Kleitmann, W., 39
Cheshik, S.G. *see* Slepushkin, A.N., 25
Chiron, J.-P. *see* Coursaget, P., 357
Cioni, C. *see* Ubertini, T.R., 481
Clark, S.J. *see* Greenwood, P.E., 389
Clements, J.D., Hartzog, N.M. and Lyon, F.L. Adjuvant activity of *Escherichia coli* heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens, 269
Coelingh, K.V.W. *see* Chanock, R.M., 129
Cohen, J.H.M. *see* Fessard, C., 469
Collins, P.L. *see* Olmsted, R.A., 519
Collins, P.L. *see* Chanock, R.M., 129
Coursaget, P., Adamowicz, P., Bourdil, C., Yvonnet, B., Buisson, Y., Barres, J.L., Saliou, P., Chiron, J.-P. and Mar, I.D. Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization, 357
Cox, J. *see* Kleitmann, W., 39
Cox, N.J. *see* De, B.K., 257
Curtiss, R., Goldschmit, R.M., Fletchall, N.B. and Kelly, S.M. Avirulent *Salmonella typhimurium* Δcya Δcrp oral vaccine strains expressing a streptococcal colonization and virulence antigen, 155
Czuprynski, C.J. *see* Noel, E.J., 433

Dale, J.B. *see* Beachey, E.H., 192
Dalgleish, A.G. and Kennedy, R.C. Anti-idiotype antibodies as immunogens: idiotype-based vaccines, 215
Danse, L.H.J.C. *see* Speijers, G.J.A., 419
Day, A. *see* Rutter, D.A., 29
Dbaly, V. *see* Kutinova, L., 223
De, B.K., Shaw, M.W., Rota, P.A., Harmon, M.W., Esposito, J.J., Rott, R., Cox, N.J. and Kendal, A.P. Protection against virulent H5 avian influenza infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus, 257
den Hartigh, G. *see* Heijtink, R.A., 59
Derks, H.J.G.M. *see* Speijers, G.J.A., 419
Desmettre, P. *see* Taylor, J., 497
Deveikis, A., Ward, J. and Kim, K.S. Functional activities of human antibody induced by the capsular polysaccharide or polysaccharide-conjugate vaccines against *Haemophilus influenzae* type b, 14
Dewar, J.B. *see* Martin, M.E.D., 33
Diderrich, G. *see* Barth, R., 369
Domorazkova, E. *see* Kutinova, L., 223
Doutlik, S. *see* Kutinova, L., 223
Dubois, D.R. *see* Eckels, K.H., 513

Eckels, K.H., Yong-Xin, Y., Dubois, D.R., Marchette, N.J., Trent, D.W. and Johnson, A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaption to primary canine kidney cell cultures and preparation of a vaccine for human use, 513
EEC Research Working Party on AIDS. Towards anti-HIV vaccines, 211
Eichmann, K. and Emmrich, F. Selective induction of T-cell subsets by antibodies to the T-cell antigen receptor and the subset-specific differentiation antigens CD8 and CD4, 85

Emmrich, F. *see* Eichmann, K., 85
Emod, J. *see* Joo, I., 233
Ertl, H.C.J. and Bona, C.A. Criteria to define anti-idiotypic antibodies carrying the internal image of an antigen, 80
Esposito, J.J. *see* De, B.K., 257
Ezeokoli, C.D. *see* Okoh, A.E.J., 19

Farag-Mahmod, F.I., Wyde, P.R., Rosborough, J.P. and Six, H.R. Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice, 262
Fekadu, M., Shaddock, J.H., Sanderlin, D.W. and Smith, J.S. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (*Eptesicus serotinus*) classic rabies and rabies-related viruses, 533
Fernandez, E. *see* Bergmann, I.E., 245
Ferris, N.P. *see* Kitching, R.P., 403
Fessard, C., Riche, O. and Cohen, J.H.M. Intramuscular versus subcutaneous injection for hepatitis B vaccine, 469
Fletchall, N.B. *see* Curtiss, R., 155
Flexner, C. *see* Moss, B., 161
Flores, J. *see* Chanock, R.M., 129
Freudenstein, H., Weinmann, E. and Hill, I. Potency testing of BCG vaccines on white mice: influence of variables on survival time, lung findings and vaccine assessment, 315
Fuerst, T.R. *see* Moss, B., 161
Fujita, C. *see* Saiki, I., 238
Fukai, K. *see* Yamanishi, K., 278
Fukuda, T. *see* Azuma, I., 339
Funnell, S. *see* Rutter, D.A., 29

Gagnoni, S. *see* Ubertini, T.R., 481
Gerfaux, G. *see* Langevin-Perriat, A., 509
Gerlier, D. *see* Mougin, B., 445
Gibbs, C.J. *see* Goudsmit, J., 229
Gibson, C.A., Schlesinger, J.J. and Barrett, A.D.T. Prospects for a virus non-structural protein as a subunit vaccine, 7
Goddard, R.D., Nicholas, R.A.J. and Luff, P.R. Serology-based potency test for inactivated Newcastle disease vaccines, 530
Goldschmit, R.M. *see* Curtiss, R., 155
Gonzalez-Carrero, M.I. *see* Mills, S.D., 116
Good, M.F. *see* Miller, L.H., 104
Goudsmit, J., Thiriart, C., Smit, L., Bruck, C. and Gibbs, C.J. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees, 229
Greenwood, P.E., Clark, S.J., Cahill, A.D., Trevallyn-Jones, J. and Tzipori, S. Development and protective efficacy of recombinant-DNA derived fimbrial vaccine against enterotoxic colibacillosis in neonatal piglets, 389
Gupta, C.K. *see* Sokhey, J., 12
Gupta, R.K., Saxena, S.N., Sharma, S.B. and Ahuja, S. Studies on the optimal conditions for inactivation of *Bordetella pertussis* organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine, 491

Hackett, J. *see* Attridge, S., 387
Hagopian, R.A. *see* Satterthwait, A.C., 99
Haiva, V.-M. *see* Koskela, P., 221
Hanson, S.K. *see* Katz, J.B., 6
Harmon, M.W. *see* De, B.K., 257
Harmon, M.W. *see* Slepushkin, A.N., 25
Hartzog, N.M. *see* Clements, J.D., 269
Hasegawa, A. *see* Ishida, H., 440
Hasegawa, A. *see* Saiki, I., 238
Hashiguchi, Y. *see* Ueda, K., 54
Heijtink, R.A., Breukers, A.A.F.M., den Hartigh, G., Schepman, R.W.M., Schmitz, P.I.M., Schalm, S. and Masurel, N. Low dose intradermal vaccination against hepatitis B in mentally retarded patients, 59
Hill, I. *see* Freudenstein, H., 315
Hilleman, M.R. Hepatitis B and AIDS and the promise of their control by vaccines, 175
Hishiyama, M., Tsurudome, M., Ito, Y., Yamada, A. and Sugiura, A. Complement-mediated neutralization test for determination of mumps vaccine-induced antibody, 423
Hoglund, S. *see* Sundquist, B., 44
Hugin, A. *see* Moss, B., 161

Iida, J. *see* Saiki, I., 238
Iida, J. *see* Azuma, I., 339
Iizuka, N. *see* Nomoto, A., 134
Ikawa, Y. *see* Ohishi, K., 428
Insel, R.A. *see* Anderson, P. 188
Isaeva, E.S. *see* Berezin, V.E., 450
Ishida, H. *see* Saiki, I., 238
Ishida, H., Saiki, I., Saito, S., Hasegawa, A., Kiso, M. and Azuma, I. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues, 440
Ishihara, Y. *see* Ueda, K., 54
Israel, B.A. *see* Noel, E.J., 433
Israel, B.A., Marshall, R.L. and Letchworth III, G.J. Epitope specificity and protective efficacy of the bovine immune response to bovine herpesvirus-1 glycoprotein vaccines, 349
Ito, Y. *see* Hishiyama, M., 423

Joffret, M.L. *see* Perrin, P., 331
Johnson, A.J. *see* Eckels, K.H., 513
Joklik, W.K., Pickup, D.J., Patel, D.D. and Moody, M.D. Virulence genes of poxviruses and reoviruses, 123
Joo, I. and Emod, J. Adjuvant effect of DEAE-dextran on cholera vaccines, 233
Just, M. and Berger, R. Immunogenicity of a heat-treated recombinant DNA hepatitis B vaccine, 399
Just, M., Berger, R. and Scheiermann, N. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine, 401

Kalos, Z. *see* Kutinova, L., 223
Kaminkova, J. *see* Kutinova, L., 223
Kaper, J.B. and Levine, M.M. Progress towards a vaccine against enterotoxigenic *Escherichia coli*, 197
Kaptsova, T.I. *see* Boriskin, Y.S., 483
Karnell, A. *see* Lindberg, A.A., 146
Katakura, S. *see* Lindberg, A.A., 146
Katz, J.B. and Hanson, S.K. Encephalomyelitis vaccines: a Vero-derived cell culture alternative to primary duck embryonic cell cultures, 6
Kawaoka, Y. *see* Taylor, J., 504
Kelly, S.M. *see* Curtiss, R., 155
Kendal, A.P. *see* De, B.K., 257
Kennedy, R.C. *see* Dalgleish, A.G., 215
Kim, K.S. *see* Deveikis, A., 14
Kingsman, A.J. *see* Kingsman, S.M., 304
Kingsman, S.M. and Kingsman, A.J. Polyvalent recombinant antigens: a new vaccine strategy, 304
Kiso, M. *see* Ishida, H., 440
Kitchen, L.W. Effect of diethylcarbamazine on serum antibodies to feline infectious peritonitis in cats, 10
Kitching, R.P., Rendle, R. and Ferris, N.P. Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus, 403
Kleitmann, B. *see* Kleitmann, W., 39
Kleitmann, W., Kleitmann, B., Cox, J. and Charbonnier, C. Effectivenesss and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line, 39
Kobayashi, S. *see* Azuma, I., 339
Kohara, M. *see* Nomoto, A., 134
Kondo, K. *see* Yamanishi, K., 278
Konobe, T. *see* Yamanishi, K., 278
Koskela, P., Nurmi, T. and Haiva, V.-M. IgA, IgG and IgM anti-blood group A antibodies induced by pneumococcal vaccine, 221
Kraus, W. *see* Beachey, E.H., 192
Kreuter, J., Liehl, E., Berg, U., Soliva, M. and Speiser, P.P. Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants, 253
Kroll, J.S. *see* Moxon, E.R., 113
Kupryashina, L.N. *see* Slepushkin, A.N., 25
Kurata, H. *see* Tamura, S., 409
Kurata, T. *see* Tamura, S., 409
Kutinova, L., Benda, R., Kalos, Z, Dbaly, V., Votruba, T., Kvicalova, E., Petrovska, P., Doutlik, S., Kaminkova, J., Domorazkova, E., Bergmanova, V., Krcmar, M., Suchankova, A., Nemeckova, S. and Vonka, V. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences, 223
Kvicalova, E. *see* Kutinova, L., 223

La Torre, J.L. *see* Bergmann, I.E., 245
Lafon, M. *see* Vodopija, I., 283, 489
Lafon, M., Bourhy, H. and Sureau, P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice, 362
Lafont, S. *see* Langevin-Perriat, A., 509
Langevin-Perriat, A., Lafont, S., Vincent, C., Revillard, J-P., Mazert, M-C., Gerfaux, G. and Tron, F. Intestinal secretory antibody response induced by an oral cholera vaccine in human volunteers, 509
Langley, D. and Spier, R.E. Is a vaccine against AIDS possible?, 3
Languet, B. *see* Taylor, J., 497
Leclerc, C. *see* Perrin, P., 331
Lerner, R.A. *see* Satterthwait, A.C., 99
Letchworth III, G.J. *see* Israel, B.A., 349
Letchworth III, G.J. *see* Noel, E.J., 433
Letchworth III, G.J. *see* Marshall, R.L., 343
Levine, M.M. *see* Tacket, C.O., 307
Levine, M.M. *see* Kaper, J.B., 197
Liehl, E. *see* Kreuter, J., 253
Lindberg, A.A., Karnell, A., Stocker, B.A.D., Katakura, S., Sweiha, H. and Reinholt, F.P. Development of an auxotrophic oral live *Shigella flexneri* vaccine, 146
Lindberg, E. *see* Lund, B., 110
Ljubicic, M. *see* Vodopija, I., 283, 489
London, W.T. *see* Olmsted, R.A., 519
Lonskaya, N.I. *see* Slepushkin, A.N., 25
Lotte, V.D. *see* Boriskin, Y.S., 483
Lovell, F. *see* Rutter, D.A., 29
Lovgren, K. *see* Sundquist, B., 44, 49
Luff, P.R. *see* Goddard, R.D., 530
Lund, B., Lindberg, F., Marklund, B-I. and Normark, S. Tip proteins of pili associated with pyelonephritis: new candidates for vaccine development, 110
Lussier, G. *see* Trudel, M., 525
Lyon, F.L. *see* Clements, J.D., 269

Mar, I.D. *see* Coursaget, P., 357
Marchette, N.J. *see* Eckels, K.H., 513
Marklund, B-I. *see* Lund, B., 110
Marshall, R.L. *see* Israel, B.A., 349
Marshall, R.L. and Letchworth III, G.J. Passively administered neutralizing monoclonal antibodies do not protect calves against bovine herpesvirus 1 infection, 343
Martin, M.E.D., Dewar, J.B. and Newman, J.F.E. Polymerized serum albumin beads possessing slow release properties for use in vaccines, 33
Maruyama, T. *see* Ohishi, K., 428
Masurel, N. *see* Heijtink, R.A., 59
Matsumoto, S. *see* Ueda, K., 54
Mazert, M-C. *see* Langevin-Perriat, A., 509
Mazzuca, G. *see* Bergmann, I.E., 245
McBride, B.W., Ridgeway, P., Phillpotts, R. and Newell, D.G. Mucosal antibody response to vaginal infection with herpes simplex virus in pre-vaccinated guinea-pigs, 414
Mekalanos, J. *see* Taylor, R., 151
Michiloff, C.A. *see* Bergmann, I.E., 245
Miki, K. *see* Ohishi, K., 428
Mills, S.D., Sekizaki, T., Gonzalez-Carrero, M.I. and Timmis, K.N. Analysis and genetic manipulation of *Shigella* virulence determinants for vaccine development, 116
Mitchell, G.F., The way ahead for vaccines and vaccination: symposium summary, 200
Mizuno, K. *see* Ueda, K., 54
Moody, M.D. *see* Joklik, W.K., 123
Morein, B. *see* Sundquist, B., 44, 49
Morona, R. *see* Attridge, S., 387
Moss, B. *see* Chanock, R.M., 129
Moss, B., Fuerst, T.R., Flexner, C. and Hugin, A. Roles of vaccinia virus in the development of new vaccines, 161
Mougin, B., Bakouche, O. and Gerlier, D. Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs, 445
Moxon, E.R. and Kroll, J.S. Type b capsular polysaccharide as a virulence factor for *Haemophilus influenzae*, 113
Murata, J. *see* Saiki, I., 238
Murphy, B.R. *see* Chanock, R.M., 129
Murphy, B.R. *see* Olmsted, R.A., 519
Murray, K. Application of recombinant DNA techniques in the development of viral vaccines, 164

Nadon, F. *see* Trudel, M., 525
Nagamine, T. *see* Tamura, S., 409
Nalin, D.R. Blood group A substances are not present in currently available pneumococcal vaccine, 469
Newell, D.G. *see* McBride, B.W., 414
Newman, J.F.E. *see* Martin, M.E.D., 33
Nicholas, R.A.J. *see* Goddard, R.D., 530
Nishimaki, J. *see* Ohishi, K., 428
Noel, E.J., Israel, B.A., Letchworth III, G.J. and Czuprynski, C.J. Effects of immunization with bovine herpesvirus-1 glycoproteins on bovine herpesvirus-1-induced alteration of bovine neutrophil chemotactic and anti-*Pasteurella haemolytica* activities, 433
Nomoto, A., Iizuka, N., Kohara, M. and Arita, M. Strategy for construction of live picornavirus vaccines, 134
Nonaka, S. *see* Ueda, K., 54
Normark, S. *see* Lund, B., 110
Nurmi, T. *see* Koskela, P., 221
Nussenzweig, V. *see* Satterthwait, A.C., 99

Obrosova-Serova, N.P. *see* Slepushkin, A.N., 25
Ohishi, K., Maruyama, T., Shida, H., Nishimaki, J., Miki, K., Sagata, N., Ikawa, Y. and Sugimoto, M. Immunogenicity of a recombinant vaccinia virus expressing envelope glycoprotein of bovine leukaemia virus, 428
Okoh, A.E.J., Umoh, J.U., Ezeokoli, C.D. and Addo, P.B. Vaccination challenge studies with variants of street rabies virus isolated in Nigeria, 19
Olmsted, R.A. *see* Chanock, R.M., 129
Olmsted, R.A., Buller, R.M.L., Collins, P.L., London, W.T., Beeler, J.A., Prince, G.A., Chanock, R.M. and Murphy, B.R. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus, 519
Orvell, C. *see* Boriskin, Y.S., 483
Oth, D. *see* Perrin, P., 331

Paoletti, E. *see* Taylor, J., 466, 497, 504
Papaevangelou, G. *see* Tsalalakis, C., 328
Patel, D.D. *see* Joklik, W.K., 123
Patriarca, P.A. *see* Slepushkin, A.N., 25
Perini, L. *see* Ubertini, T.R., 481
Perlman, H. *see* Perlmann, P., 183
Perlmann, P., Berzins, K., Perlmann, H., Troye-Blomberg, M., Wahlgren, M. and Wahlin, B. Malaria vaccines: immunogen selection and epitope mapping, 183
Perrin, P., Joffret, M.L., Oth, D., Leclerc, C., Sureau, P. and Thibodeau, L. Interleukin-2 production *in vitro*: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations, 331
Peterson, K. *see* Taylor, R., 151
Petrovska, P. *see* Kutinova, L., 223
Phillpotts, R., *see* McBride, B.W., 414
Pickup, D.J. *see* Joklik, W.K., 123
Poirier, T. *see* Beachey, E.H., 192
Polezhaev, F.I. *see* Slepushkin, A.N., 25
Poore, P. Vaccination strategies in developing countries, 393
Prince, G.A. *see* Chanock, R.M., 129
Prince, G.A. *see* Olmsted, R.A., 519

Reinholt, F.P. *see* Lindberg, A.A., 146
Rendle, R. *see* Kitching, R.P., 403
Revillard, J-P. *see* Langevin-Perriat, A., 509
Richardson, S.C. *see* Tsalalakis, C., 328
Riche, O. *see* Fessard, C., 469
Ridgeway, P. *see* McBride, B.W., 414
Robbins, J.B. *see* Tacket, C.O., 307
Robinson, A. *see* Rutter, D.A., 29
Rosborough, J.P. *see* Farag-Mahmod, F.I., 262
Rota, P.A. *see* De, B.K., 257
Rott, R. *see* De, B.K., 257
Roumeliotou-Karayannis, A. *see* Tsalalakis, C., 328
Rutter, D.A., Ashworth, L.A.E., Day, A., Funnell, S., Lovell, F. and Robinson, A. Trial of a new acellular pertussis vaccine in healthy adult volunteers, 29

Sagata, N. *see* Ohishi, K., 428
Saiki, I. *see* Ishida, H., 440

Saiki, I. *see* Azuma, I., 339
Saiki, I., Saito, S., Fujita, C., Ishida, H., Iida, J., Murata, J., Hasegawa, A. and Azuma, I. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues, 238
Saint-Gerand, A.L. Towards a second generation of inactivated vaccines: the use of herpesvirus (feline rhinotracheitis virus) subunits for the prevention of cat flu, 468
Saito, S. *see* Ishida, H., 440
Saito, S. *see* Saiki, I., 238
Saliou, P. *see* Coursaget, P., 357
Samegai, Y. *see* Tamura, S., 409
Sanderlin, D.W. *see* Fekadu, M., 533
Sargent, S. *see* Beachey, E.H., 192
Satterthwait, A.C., Arrhenius, T., Hagopian, R.A., Zavala, F., Nussenzweig, V. and Lerner, R.A. Conformational restriction of petidyl immunogens with covalent replacements for the hydrogen bond, 99
Saxena, S.N. *see* Gupta, R.K., 491
Schalm, S.W. *see* Heijtink, R.A., 59
Scheiermann, N. *see* Just, M., 401
Schepman, R.W.M. *see* Heijtink, R.A., 59
Schlesinger, J.J. *see* Gibson, C.A., 7
Schmitz, P.I.M. *see* Heijtink, R.A., 59
Scodeller, E.A. *see* Bergmann, I.E., 245
Seguin, C. *see* Trudel, M., 525
Seifert, H.S., Ajioka, R. and So, M. Alternative model for *Neisseria gonorrhoeae* pilin variation, 107
Sekizaki, T. *see* Mills, S.D., 116
Sercarz, E.E. *see* Celada, F., 94
Shaddock, J.H. *see* Fekadu, M., 533
Sharma, B. *see* Sokhey, J., 12
Sharma, S.B. *see* Gupta, R.K., 491
Shaw, C. *see* Taylor, R., 151
Shaw, M.W. *see* De, B.K., 257
Shida, H. *see* Ohishi, K., 428
Shigaki, T. *see* Ueda, K., 54
Simard, C. *see* Trudel, M., 525
Singh, H.. *see* Sokhey, J., 12
Six, H.R. *see* Farag-Mahmod, F.I., 262
Skvortsova, O.I. *see* Boriskin, Y.S., 483
Slepushkin, A.N., Patriarca, P.A., Obrosova-Serova, N.P., Harmon, M.W., Kupryashina, L.N., Cheshik, S.G., Vartanyan, R.B., Alexandrova, G.I., Polezhaev, F.I., Lonskaya, N.I., Yagodovskii, B.V., Kendal, A.P. and Zhdanov, V.M. Class-specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)-like recombinant influenza virus prepared from the A/Leningrad/134/57 paediatric cold-adapted donor strain, 25
Smerdel, S. *see* Vodopija, I., 283, 489
Smit, L. *see* Goudsmit, J., 229
Smith, J.S. *see* Fekadu, M., 533
Snyder, M.H. *see* Chanock, R.M., 129
So. M. *see* Seifert, H.S., 107
Sokhey, J., Gupta, C.K., Sharma, B. and Singh, H. Stability of oral polio vaccine at different temperatures, 12
Soliva, M. *see* Kreuter, J., 253
Spears, P. *see* Taylor, R., 151
Speijers, G.J.A., Danse, L.H.J.C., Beuvery, E.C., Derks, H.J.G.M. and Vos, J.G. Local reactions of Zwittergent-containing meningococcal vaccine after intramuscular injection in rats: comparison with the effect of diphtheria–pertussis–tetanus–polio vaccine, 419
Speiser, P.P. *see* Kreuter, J., 253
Spier, R.E. *see* Langley, D., 3
Spriggs, M.K. *see* Chanock, R.M., 129
Stephenne, J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness, 299
Stephenson, J.R. Flavivirus vaccines, 471
Stocker, B.A.D. *see* Lindberg, A.A., 146
Stocker, B.A.D. Auxotrophic *Salmonella typhi* as live vaccine, 141
Sugimoto, M. *see* Ohishi, K., 428
Sugiura, A. *see* Hishiyama, M., 423
Sundquist, B., Lovgren, K. and Morein, B. Influenza virus ISCOMs: antibody response in animals, 49
Sundquist, B., Lovgren, K., Hoglund, S. and Morein, B. Influenza virus ISCOMs: biochemical characterization, 44
Sureau, P. *see* Vodopija, I., 283, 489
Sureau, P. *see* Lafon, M., 362
Sureau, P. *see* Perrin, P., 331
Svjetlicic, M. *see* Vodopija, I., 283, 489
Sweiha, H. *see* Lindberg, A.A., 146

Tacket, C.O., Levine, M.M. and Robbins, J.B. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever, 307
Takagi, M. *see* Yamanishi, K., 278
Tamura, M. *see* Yamanishi, K., 278
Tamura, S., Samegai, Y., Kurata, H., Nagamine, T., Aizawa, C., and Kurata, T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit, 409
Tanishita, O. *see* Yamanishi, K., 278
Tashiro, A. *see* Ueda, K., 54
Taylor, J., Weinberg, R., Languet, B., Desmettre, P. and Paoletti, E. A recombinant fowlpox virus induces protective immunity in non-avian species, 479
Taylor, J. and Paoletti, E. Fowlpox virus as a vector in non-avian species, 466
Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R.G. and Paoletti, E. Protective immunity against avian influenza induced by a fowlpox virus recombinant, 504
Taylor, R., Shaw, C., Peterson, K., Spears, P. and Mekalanos, J. Safe, live *Vibrio cholerae* vaccines?, 151
Thibodeau, L. *see* Perrin, P., 331
Thiriart, C. *see* Goudsmit, J., 229
Timmis, K.N. *see* Mills, S.D., 116
Tiraboschi, B. *see* Bergmann, I.E., 245
Tokugawa, K. *see* Ueda, K., 54
Trent, D.W. *see* Eckels, K.H., 513
Trevallyn-Jones, J. *see* Greenwood, P.E., 389
Tron, F. *see* Langevin-Perriat, A., 509
Troye-Blomberg, M. *see* Perlmann, P., 183
Trudel, M., Boulay, G., Seguin, C., Nadon, F. and Lussier, G. Control of infectious bovine rhinotracheitis in calves with a BHV-1 subunit-ISCOM vaccine, 525
Tsalalakis, C., Richardson, S.C., Roumeliotou-Karayannis, A. and Papaevangelou, G. Immunogenicity of low doses of recombinant hepatitis B vaccine in young males, 328
Tsurudome, M. *see* Hishiyama, M., 423
Tzipori, S. *see* Greenwood, P.E., 389

Ubertini, T.R., Cioni, C., Perini, L. and Gagnoni, S. Non-neurovirulent, genetically stable clone of poliovirus (Sabin type III vaccine strain), 481
Uchimura, H. *see* Ueda, K., 54
Ueda, K., Tokugawa, K., Hashiguchi, Y., Matsumoto, S., Uchimura, H., Shigaki, T., Ishihara, Y., Mizuno, K., Tashiro, A. and Nonaka, S. Prevention of horizontal transmission of hepatitis B: efficacy of hepatitis B immunoglobulin and vaccine in an institution for the handicapped, 54
Umoh, J.U. *see* Okoh, A.E.J., 19

Vartanyan, R.B. *see* Slepushkin, A.N., 25
Vincent, C. *see* Langevin-Perriat, A., 509
Vodopija, I., Sureau, P., Smerdel, S., Lafon, M., Baklaic, Z., Ljubicic, M., and Svjetlicic, M. Comparative study of two human diploid rabies vaccines given with antirabies globulin, 489
Vodopija, I., Sureau, P., Smerdel, S., Lafon, M., Baklaic, Z., Ljubicic, M., and Svjetlicic, M. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2–1–1 schedule application for post-exposure treatment, 283
Vox, J.G. *see* Speijers, G.J.A., 419
Votruba, T. *see* Kutinova, L., 223

Wahlgren, M. *see* Perlmann, P., 183
Wahlin, B. *see* Perlmann, P., 183
Ward, J. *see* Deveikis, A., 14
Webster, R.G. *see* Taylor, J., 504
Weinberg, R. *see* Taylor, J., 497, 504
Weinmann, E. *see* Barth, R., 369
Weinmann, E. *see* Freudenstein, H., 315
Whyte, P. *see* Attridge, S., 387
Wyde, P.R. *see* Farag-Mahmod, F.I., 262

Yamada, A. *see* Hishiyama, M., 423
Yamanishi, K., Tanishita, O., Tamura, M., Asada, H., Kondo, K., Takagi, M., Yoshida, I., Konobe, T. and Fu-

kai, K. Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome, 278
Yong-Xin, Y. *see* Eckels, K.H., 513
Yoshida, I. *see* Yamanishi, K., 278
Yvonnet, B. *see* Coursaget, P., 357
Zaides, V.M. *see* Berezin, V.E., 450
Zavala, F. *see* Satterthwait, A.C., 99
Zhdanov, *see* Berezin, V.E., 450

Subject Index

Acellular vaccine: *see* Pertussis, 29
Adhesin protein: *see* Pyelonephritis, 110
Adjuvant: *see* Influenza, 409
Adjuvant: *see* Polymerized protein, 33
Adjuvanticity: *see* Cholera, 233
Adjuvanticity: *see Escherichia coli* enterotoxin, 269
Adjuvanticity: *see* Muramyl dipeptide analogues, 238
Adjuvanticity: *see* Muramyl dipeptides, 339
Adjuvanticity: *see* Polymeric adjuvants, 253
AIDS: *see* Hepatitis B, 175
AIDS: *see* HIV, 211, 229
AIDS: Is a vaccine against AIDS possible?, 3
AIDS: Testing for AIDS on samples of dried blood on filter papers, 210
AIDS: *see* Immune response, 77
AIDS: *see* T cell, 89
Antibody activity: *see Haemophilus influenzae*, 14
Antibody, to CD8, CD4: *see* T cell, 85
Antigen: *see* Anti-idiotype, 80
Antigen processing: *see* Cross immunogenicity, 94
Antigen tolerance: *see Escherichia coli* enterotoxin, 269
Anti-A antibodies: *see* Pneumococcal vaccine, 221
Anti-idiotype: Criteria to define anti-idiotypic antibodies carrying the internal image of an antigen, 80
Anti-idiotype: Anti-idiotype antibodies as immunogens: idiotype-based vaccines, 215
Anti-pre-S2 antibody: *see* Hepatitis B, 357
Attenuated vaccine: *see* Influenza, 25
Attenuated virus: Live viral vaccines for respiratory and enteric tract diseases, 129
Attenuation: *see* Japanese encephalitis virus, 513
Attenuation: *see* Mumps, 483
Attenuation *see* Picornavirus, 134
Attenuation: *see Shigella flexneri*, 146
Attenuation: *see* Vaccinia virus, 161
Auxotroph: *see Salmonella typhi*, 141
Auxotroph: *see Shigella flexneri*, 146

Bat rabies, European: *see* Rabies, 362
Bats: *see* Duvenhage, virus, 533
BCG vaccine: Potency testing of BCG vaccines on white mice: influence of variables on survival time, lung findings and vaccine assessment, 315
Blood group A substance: *see* Pneumococcal vaccine, 221, 469
Bovine herpesvirus: *see* Infectious bovine rhinotracheitis, 525
Bovine leukaemia virus: *see* Vaccinia vector, 428

Capsular polysaccharide: *see Haemophilus influenzae*, 113, 188
Challenge: *see* Rabies, 19
Chickens: *see* Influenza, 257
Children: *see* Influenza, 25
Cholera: Adjuvant effect of DEAE-dextran on cholera vaccines, 233
Cholera: Intestinal secretory antibody response induced by an oral cholera vaccine in human volunteers, 509
Cholera: *see Vibrio cholerae*, 151
Cholera toxin B subunit: *see* Influenza, 409
Circumsporozoite protein: *see* Subunit vaccine, 104
Clone: *see* Poliovirus, 481
Combined vaccine: *see* Herpes simplex, 309
Complement: Complement-mediated neutralization test for determination of mumps vaccine-induced antibody, 423
Conformation: *see* Peptides, synthetic, 99
Cord fctor analogue: *see* Muramyl deptide analogue, 440
Core antigen: *see* Recombinant DNA, 164
Cost–benefit analysis: *see* Herpes simplex, 309
Cowpox virus: *see* Virulence genes, 123
Cross immunogenicity: Preferential pairing of T–B specificities in the same antigen: the concept of directional help, 94
Cross-neutralization: *see* HIV, 229

DEAE-dextran: *see* Cholera, 233
Degradation tests: enhancement of field stability and utility of future biologicals through prior accelerated degradation testing, 386
Design: *see* AIDS, 3
Design: *see* Flavivirus, 471
Diagnosis: *see* AIDS, 210
Diethylcarbamazine: *see* Feline infectious peritonitis, 10
Duvenhage virus: *see* Rabies, 362
Duvenhage virus: Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (*Eptesicus serotinus*) classic rabies and rabies-related viruses, 533

Efficacy: *see* Molecular vaccine, 200
ELISA: *see* Foot-and-mouth disease, 403
Encephalomyelitis: Encephalomyelitis vaccines: a Vero-derived cell culture alternative to primary duck embryonic cell cultures, 6
Enterotoxigenic *E. coli: see* Scours, 387, 389
Enterotoxigenics: *see Escherichia coli*, 197
Envelope glycoprotein: *see* Herpesvirus 1, bovine, 343, 349
Envelope glycoprotein: *see* Subunit vaccine, 450
Envelope glycoprotein: *see* Vaccinia vector, 428
Epitope: *see* Malaria, 183
Epitope: *see Streptococcus pyogenes*, 192
Epitope: *see* T cell, 89
Escherichia coli: Progress towards a vaccine against enterotoxigenic *Escherichia coli*, 197
Escherichia coli: *see* Scours, 387
Escherichia coli enterotoxin: Adjuvant activity of *Escherichia coli* heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens, 269
Expanded Programme on Immunization: *see* Strategy for vaccination, 393

Feline infectious peritonitis: Effect of diethylcarbamazine on serum antibodies to feline infectious peritonitis in cats, 10
Feline rhinotracheitis virus: *see* Herpesvirus, 468
Fertility control: *see* Immune response, 77
Flavivirus: Flavivirus vaccines, 471
Flavivirus: Prospects for a virus nonstructural protein as a subunit vaccine, 7
Foot-and-mouth disease: Rapid correlation between field isolates and vaccine strains of foot-and-mouth disease virus, 403

Foot-and-mouth disease: Use of peptides for immunization against foot-and-mouth disease, 180
Foot-and-mouth disease: Serological and biochemical analysis of foot-and-mouth disease virus (serotype C3) isolated in Argentina between 1981 and 1986, 245
Fowlpox virus vector: Fowlpox virus as a vector in non-avian species, 466
Fowlpox virus vector: Protective immunity against avian influenza induced by a fowlpox virus recombinant, 504
Fowlpox virus vector: Recombinant fowlpox virus induces protective immunity in non-avian species, 497

Glutaraldehyde: *see* Pertussis, 491
Glycoprotein: *see* Vaccinia vector, 519
Glycoprotein presentation: *see* Rabies, 331
Glycoprotein vaccines: *see* Herpesvirus 1, bovine, 349
Glycoproteins: *see* Herpesvirus-1, bovine, 433
Glycoproteins: *see* Measles, 445

Haemagglutinin: *see* Influenza virus, 44, 49
Haemophilus influenzae: Functional activities of human antibody induced by the capsular polysaccharide or polysaccharide-conjugate vaccines against *Haemophilus influenzae* type b, 14
Haemophilus influenzae: Type b capsular polysaccharide as a virulence factor for *Haemophilus influenzae*, 113
Haemophilus influenzae: Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of *Haemophilus influenzae* type b,188
Haemorrhagic fever with renal syndrome: Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome, 278
Hantaan virus: *see* Haemorrhagic fever with renal syndrome, 278
Hepatitis B: Hepatitis B and AIDS and the promise of their control by vaccines, 175
Hepatitis B: *see* Anti-idiotype, 215
Hepatitis B: Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization, 357
Hepatitis B: Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine, 401
Hepatitis B: Prevention of horizontal transmission of hepatitis B: efficacy of hepatitis B immunoglobulin and vaccine in an institution for the handicapped, 54
Hepatitis B: Low dose intradermal vaccination against hepatitis B in mentally retarded patients, 59
Hepatitis B: Intramuscular versus subcutaneous injection for hepatitis B vaccine, 469
Hepatitis B: *see* Recombinant DNA, 164
Hepatitis B: Immunogenicity of low doses of recombinant hepatitis B vaccine in young males, 328
Hepatitis B: Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness, 299
Hepatitis B: Immunogenicity of a heat-treated recombinant DNA hepatitis B vaccine, 399
Hepatocarcinoma: *see* Muramyl deptide analogue, 440
Herpes simplex: Hypothermal vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model, 309
Herpes simplex: Mucosal antibody response to vaginal infection with herpes simplex virus in pre-vaccinated guinea-pigs, 414
Herpes simplex: Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences, 223
Herpesvirus: Towards a second generation of inactivated vaccines: use of herpesvirus (feline rhinotracheitis virus) subunits for the prevention of cat flu, 468
Herpesvirus 1, bovine: Epitope specificity and protective efficacy of the bovine immune response to bovine herpesvirus-1 glycoprotein vaccines, 349
Herpesvirus 1, bovine: Passively administered neutralizing monoclonal antibodies do not protect calves against bovine herpesvirus 1 infection, 343
Herpesvirus-1, bovine: Effects of immunization with bovine herpesvirus-1 glycoproteins on bovine herpesvirus-1-induced alteration of bovine neutrophil chemotactic and anti-*Pasteurella haemolytica* activities, 433
HIV: *see* AIDS, 3, 210
HIV: Towards anti-HIV vaccines, 211
HIV: Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees, 229
HIV: *see* Anti-idiotype, 215
HIV: *see* Hepatitis B, 175
Hybrid vaccine: *see Shigella dysenteriae*, 116

Immune response: What to expect of a good vaccine and how to achieve it, 77
Immunity: *see* Flavivirus, 7
Immunogen: *see* Malaria, 183
Immunogen: *see* Polysaccharide vaccine, 138
Immunogenicity: *see* Hepatitis B, 299, 328, 401
Immunogenicity: *see* Influenza, 262
Immunogenicity: *see* Molecular vaccine, 200
Immunogenicity: *see* Pertussis, 29
Immunogenicity: *see* Subunit vaccine, 450
Immunoglobulin: *see* Hepatitis B, 54
Immunoglobulin: *see* Rabies, 283, 489
Immunodulation: *see* Muramyl dipeptide analogues, 238
Immunomodulator drugs: *see* Feline infectious peritonitis, 10
Inactivated vaccine: *see* Newcastle disease, 530
Inactivation: *see* Pertussis, 491
Induction, *see* T cell, 85
Infants: *see Haemophilus influenzae*, 188
Infectious bovine rhinotracheitis: Control of infectious bovine rhinotracheitis in calves with a BHV-1 subunit-ISCOM vaccine, 525
Influenza: Class-specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)-like recombinant influenza virus prepared from the A/Leningrad/134/57 paediatric cold-adapted donor strain, 25
Influenza: Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit, 409
Influenza: Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice, 262
Influenza: Protection against virulent H5 avian influenza infection in chickens by an inactivated vaccine produced with recombinant vaccinia virus, 257
Influenza virus: Influenza virus ISCOMs: biochemical characterization, 44
Influenza virus: Influenza virus ISCOMs: antibody response in animals, 49
Influenza, avian: *see* Fowlpox virus vector, 466, 497, 504
Influenza, cat: *see* Herpesvirus, 468
Interleukin-2: *see* Rabies, 331
Intradermal: *see* Hepatitis B, 59
Intramuscular route: *see* Hepatitis B, 469
ISCOMs: *see* Infectious bovine rhinotracheitis, 525
ISCOMs: *see* Influenza virus, 44, 49

Japanese encephalitis virus: Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaption to primary canine kidney cell cultures and preparation of a vaccine for human use, 513

Laboratory markers: *see* Mumps, 483
Liposomes: *see* Measles, 445
Local reaction: *see* Meningococcal vaccine, 419

M protein: *see Streptococcus pyogenes*, 192
Malaria: Malaria vaccines: immunogen selection and epitope mapping, 183
Malaria: *see* Peptides, synthetic, 99
Malaria: *see* Subunit vaccine, 104

Measles: Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs, 445
Meningitis B: *see* Polysaccharide vaccine, 138
Meningococcal vaccine: Local reactions of Zwittergent-containing meningococcal vaccine after intramuscular injection in rats: comparison with the effect of diphtheria–pertussis–tetanus–polio vaccine, 419
Mentally retarded: *see* Hepatitis B, 59
Molecular vaccine: The way ahead for vaccines and vaccination: symposium summary, 200
Monoclonal antibodies: *see* Herpesvirus 1, bovine, 343
Morbidity: *see* Poliovirus, 213
Mucosal immunity: *see* Herpes simplex, 414
Multiprenylacetic acids: *see* Muramyl dipeptides, 339
Mumps: Laboratory markers for overattenuation of mumps vaccine virus, 483
Mumps: *see* Complement, 423
Muramyl dipeptide analogues: Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues, 238
Muramyl dipeptides: Immunological activities of multiprenylacetyl derivatives of muramyl dipeptides, 339
Muramyl deptide analogue: Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues, 440
Mycobacterium bovis: *see* BCG vaccine, 315

Neisseria gonorrhoeae: Alternative model for *Neisseria gonorrhoeae* pilin variation, 107
Neurovirulence: *see* Poliovirus, 481
Neutrophil activity: *see* Herpesvirus-1, bovine, 433
Newcastle disease: Serology-based potency test for inactivated Newcastle disease vaccines, 530
NIH test: *see* Rabies, 369
Non-structural protein: *see* Flavivirus, 7
Nosocomial transmission: *see* Hepatitis B, 54

O antigen polysaccharide: *see Shigella dysenteriae*, 116
Oral route: *see* Influenza, 262

Parainfluenza virus: *see* Attenuated virus, 129
Peptides, synthetic: Conformational restriction of petidyl imunogens with covalent replacements for the hydrogen bond, 99
Peptides, synthetic: *see* Foot-and-mouth disease, 180
Pertussis: Trial of a new acellular pertussis vaccine in healthy adult volunteers, 29
Pertussis: Studies on the optimal conditions for inactivation of *Bordetella pertussis* organisms with glutaraldehyde for prepartion of a safe and potent pertussis vaccine, 491
Picornavirus: Strategy for construction of live picornavirus vaccines, 134
Pilin: *see Neisseria gonorrhoeae*, 107
Pilus colonization factor: *see Vibrio cholerae*, 151
Pilus tip protein: *see* Pyelonephritis, 110
Placebo effect: *see* Herpes simplex, 223
Plaque neutralization: *see* Complement, 423
Pneumococcal vaccine: IgA, IgG and IgM anti-blood group A antibodies induced by pneumococcal vaccine, 221
Pneumococcal vaccine: Blood group A substances are not present in currently available pneumococcal vaccine, 469
Polio vaccine: Stability of oral polio vaccine at different temperatures, 12, 298
Poliovirus: Non-neurovirulent, genetically stable clone of poliovirus (Sabin type III vaccine strain), 481
Poliovirus: *see* Picornavirus, 134
Poliovirus: Continuing global poliomyelitis morbidity and lacunae of trivalent poliovirus vaccines, 213
Polymeric adjuvants: Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants, 253
Polymerized protein: Polymerized serum albumin beads possessing slow release properties for use in vaccines, 33
Polysaccharide conjugates: *see Haemophilus influenzae*, 14
Polysaccharide vaccine: Vaccine development reconsidered, 138
Polyvalent antigens: Polyalent recombinant antigens: a new vaccine strategy, 304
Postexposure: *see* Rabies, 283, 489
Potency: *see* Rabies, 369
Potency test: *see* Newcastle disease, 530
Potency test: *see* BCG vaccine, 315
Pre-exposure: *see* Rabies, 39
Primary canine kidney cell culture: *see* Japanese encephalitis virus, 513
Primary health care: *see* Strategy for vaccination, 393
Pyelonephritis: Tip proteins of pili associated with pyelonephritis: new candidates for vaccine development, 110

Rabies: *see* Duvenhage virus, 533
Rabies: Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice, 362
Rabies: *see* Fowlpox virus vector, 466, 497, 504
Rabies: Interleukin-2 production *in vitro*: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations, 331
Rabies: Comparative study of two human diploid rabies vaccines given with antirabies globulin, 489
Rabies: Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2–1–1 schedule application for postexposure treatment, 283
Rabies: NIH test, a problematic method for testing potency of inactivated rabies vaccine, 369
Rabies: Vaccination challenge studies with variants of street rabies virus isolated in Nigeria, 19
Rabies: Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line, 39
Recombinant DNA: *see* Hepatitis B, 399, 401
Recombinant DNA: Application of recombinant DNA techniques in the development of viral vaccines, 164
Recombinant DNA: *see* Polyvalent antigens, 304
Recombinant DNA: *see* Scours, 389
Recombinant vaccine: *see* Fowlpox virus vector, 466, 497, 504
Recombinant vaccine: *see* Hepatitis B, 328
Recombinant vaccine: *see* Influenza, 257
Recombinant vaccine: *see* Vaccinia virus, 161
Recombinant vaccine, bivalent: *see Salmonella typhimurium*, 155
Reovirus: *see* Virulence genes, 123
Respiratory syncytial virus: *see* Attenuated virus, 129
Respiratory syncytial virus: *see* Vaccinia vector, 519

Safety: *see* Hepatitis B, 299
Salmonella typhi: Auxotrophic *Salmonella typhi* as live vaccine, 141
Salmonella typhimurium: Avirulent *Salmonella typhimurium* Δcya Δcrp oral vaccine strains expressing a streptotoccal colonization and virulence antigen, 155
Scours: Towards a live oral vaccine against enterotoxigenic *Escherichia coli* of swine, 387
Scours: Development and protective efficacy of recombinant-DNA derived fimbrial vaccine against enterotoxic colibacillosis in neonatal piglets, 389
Secretory antibody response: *see* Cholera, 509
Secretory IgA: *see* Herpes simplex, 414
Serotype variants: *see* Foot-and-mouth disease, 245
Shigella dysenteriae: Analysis and genetic manipulation of *Shigella* virulence determinants for vaccine development, 116
Shigella flexneri: Development of an auxotrophic oral live *Shigella flexneri* vaccine, 146
Slow release: *see* Polymerized protein, 33

Stability: *see* Degradation tests, 386
Stability: *see* Polio vaccine, 12, 298
Stability: *see* Poliovirus, 213
Streptococcus sobrinus: *see Salmonella typhimurium*, 155
Strategy for vaccination: Vaccination strategies in developing countries, 393
Streptococcus pyogenes: Protective and autoimmune epitopes of streptococcal M proteins, 192
Subcutaneous route: *see* Hepatitis B, 469
Subtyping: *see* Foot-and-mouth disease, 403
Subunit vaccine: Controlled organization of multimolecular complexes of enveloped virus glycoproteins: study of immunogenicity, 450
Subunit vaccine: *see* Herpes simplex, 223
Subunit vaccine: The main obstacle to malaria vaccine: the malaria parasite, 104
Surface antigen: *see* Hepatitis B, 357

T cell: Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity, 89
T cell: Selective induction of T-cell subsets by anbtibodies to the T-cell antigen receptor and the subset-specific differentiation antigens CD8 and CD4, 85
Temperature: *see* Polio vaccine, 12
Temperature: *see* Polio vaccine, 298
Typhoid: *see* Vi polysaccharide, 307
T–B cooperation: *see* Cross immunogenicity, 94

Vaccinia vector: Immunogenicity of a recombinant vaccinia virus expressing envelope glycoprotein of bovine leukaemia virus, 428
Vaccinia vector: Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus, 519
Vaccinia virus: Roles of vaccinia virus in the development of new vaccines, 161
Variants: *see* Rabies, 19
Vero cells: *see* Encephalomyelitis, 6
Vero cells: *see* Rabies, 39
Vi polysaccharide: Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever, 307
Vibrio cholerae: *see* Cholera, 509
Vibrio cholerae: Safe, live *Vibrio cholerae* vaccines?, 151
Virulence genes: Virulence genes of poxviruses and reoviruses, 123

Yeast: *see* Polyvalent antigens, 304
Yeast-derived vaccine: *see* Hepatitis B, 399

Zwittergent: *see* Meningococcal vaccine, 419

BOOKS FROM BUTTERWORTHS

For an up-to-date overview of CD-ROM and CD-I technology . . .

CD-ROM: Fundamentals to Applications

Dr Charles Oppenheim

CD-ROM (compact-disc read-only memory) is the most exciting technological development to affect information specialists since the advent of online systems in the early 1970s. Although a number of books have already appeared on the subject, this is the first one to discuss the technology in detail. Written by a team of international experts, the volume takes the reader through the technology to actual case studies, outlining the problems and solutions other companies have experienced in creating CD-ROM products.

September 1988 304 pages 20 diagrams Hardcover 234 × 156 mm ISBN 0 408 00746 X £45.00

For details of other Butterworth Scientific titles, please contact the appropriate office. Orders should be sent to the appropriate office listed below. The UK headquarters serves all UK and overseas markets except where there is a local Butterworths office.

United Kingdom
Butterworths, Borough Green
Sevenoaks, Kent TN15 8PH
England

Customers in Asia may order through:
Butterworth & Co (Asia) Pte Ltd
30 Robinson Road, Unit 12-01 Tuan Sing Towers
Singapore 0104, Republic of Singapore

USA & Canada
Butterworth Publishers
80 Montvale Avenue
Stoneham, MA 02180, USA

Australia & Papua New Guinea
Butterworths Pty Ltd, PO Box 345
North Ryde, New South Wales 2113
Australia

New Zealand
Butterworths of New Zealand Ltd
33-35 Cumberland Place
Wellington 1, New Zealand